Below are the most recent publications written about "Leishmania major" by people in Profiles.
-
Martins TAF, Barbosa VS, Almeida GG, Antonelli LRDV, Tafuri WL, Mosser DM, Gon?alves R. Monocyte subpopulations as important biomarkers of resistence and susceptibility during experimental infection with Leishmania (Leishmania) major. Biomed Pharmacother. 2018 Nov; 107:1530-1539.
-
Dotiwala F, Mulik S, Polidoro RB, Ansara JA, Burleigh BA, Walch M, Gazzinelli RT, Lieberman J. Killer lymphocytes use granulysin, perforin and granzymes to kill intracellular parasites. Nat Med. 2016 Feb; 22(2):210-6.
-
Schamber-Reis BL, Petritus PM, Caetano BC, Martinez ER, Okuda K, Golenbock D, Scott P, Gazzinelli RT. UNC93B1 and nucleic acid-sensing Toll-like receptors mediate host resistance to infection with Leishmania major. J Biol Chem. 2013 Mar 08; 288(10):7127-36.
-
Morales-Tirado V, Sojka DK, Katzman SD, Lazarski CA, Finkelman FD, Urban JF, Fowell DJ. Critical requirement for the Wiskott-Aldrich syndrome protein in Th2 effector function. Blood. 2010 Apr 29; 115(17):3498-507.
-
Campos-Neto A, Suffia I, Cavassani KA, Jen S, Greeson K, Ovendale P, Silva JS, Reed SG, Skeiky YA. Cloning and characterization of a gene encoding an immunoglobulin-binding receptor on the cell surface of some members of the family Trypanosomatidae. Infect Immun. 2003 Sep; 71(9):5065-76.
-
Chakir H, Campos-Neto A, Mojibian M, Webb JR. IL-12Rbeta2-deficient mice of a genetically resistant background are susceptible to Leishmania major infection and develop a parasite-specific Th2 immune response. Microbes Infect. 2003 Apr; 5(4):241-9.
-
Skeiky YA, Coler RN, Brannon M, Stromberg E, Greeson K, Crane RT, Webb JR, Campos-Neto A, Reed SG. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine. 2002 Sep 10; 20(27-28):3292-303.
-
Coler RN, Skeiky YA, Bernards K, Greeson K, Carter D, Cornellison CD, Modabber F, Campos-Neto A, Reed SG. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun. 2002 Aug; 70(8):4215-25.
-
Campos-Neto A, Webb JR, Greeson K, Coler RN, Skeiky YA, Reed SG. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect Immun. 2002 Jun; 70(6):2828-36.
-
Campos-Neto A, Porrozzi R, Greeson K, Coler RN, Webb JR, Seiky YA, Reed SG, Grimaldi G. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun. 2001 Jun; 69(6):4103-8.